Clinical trial
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At…
NCT00240643 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00240643 |
|---|---|
| Title | Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke |
| Official title | A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fibrillation, Atrial, Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | SB424323 |
| Enrollment | 640 |
| Start date | Nov 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Oct 18, 2005 |
| Last update posted | Jan 16, 2017 |
| Countries | Argentina, Belgium, Brazil, Canada, Denmark, Estonia, France, Germany, Greece, Hungary, India, Italy and 13 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: